We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The co-founders of Taiwan-based JHL Biotech have pleaded guilty in a federal court of stealing trade secrets from Roche’s subsidiary Genentech. Read More
The companies will use Lycia’s lysosomal targeting chimera platform to develop new medicines for as many as five protein targets across different Lilly research areas. Read More
A federal appeals court has reversed a $1.2 billion ruling which found Gilead Sciences’ cancer immunotherapy Yescarta (axicabtagene ciloleucel) infringed on a Bristol Myers Squibb (BMS) patent for CAR-T technology. Read More
In addition to potential Alzheimer’s and Parkinson’s therapies, Shape said it may use its adeno-associated virus platform to help identify other gene therapy targets, including for rare diseases. Read More
South Korean conglomerate Samsung, which already manufactures Moderna’s COVID-19 vaccine, plans to increase its involvement in the biopharmaceuticals space. Read More
TTI-622 and TTI-621 are the only CD47-targeted molecules to show meaningful monotherapy activity and complete responses across multiple hematological malignancies, the companies said. Read More
Eli Lilly’s biologics division, Lilly Bio-Medicines, is splitting into two distinct units, one of which will focus entirely on approved and phase 3 drugs for pain and neurodegeneration — including Alzheimer’s disease. Read More